Literature DB >> 10093014

[Plaque stabilization by LDL apheresis?].

P Schuff-Werner1, V Schettler.   

Abstract

Vulnerable lipid-rich plaques are often the cause of atherothrombotic events leading to unstable angina and/or to acute myocardial infarction. Consequent long-term LDL-lowering by drugs as shown by the most important intervention studies lead to plaque stabilization as shown by the significant reduction of myocardial reinfarction. First studies in patients undergoing regular extracorporeal LDL-elimination indicate, that clinical events might be reduced much earlier as by drug therapy alone: A more than 60% reduction of LDL at weekly intervals is obviously associated with an early regression of lipid-rich vascular lesions. LDL-apheresis, mainly by HELP and by double filtration reduces the shear-stress of the flowing blood on vulnerable plaques either by its effect on plasmaviscosity and/or on the vasomotoric reserve thus leading to a lower peripheral arterial resistance. Furthermore oxidized LDL, which might counteract plaque stabilisation by its inflammatory effects are effectively eliminated by LDL-apheresis. The affinity of different LDL-apheresis procedures to coagulation factors normalizes hypercoagulatory states thus avoiding atherothrombotic events at the site of vulnerable or erosive plaques.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10093014     DOI: 10.1007/bf03043819

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  19 in total

1.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

2.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.

Authors:  O Tamai; H Matsuoka; H Itabe; Y Wada; K Kohno; T Imaizumi
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

3.  Coronary risk factors and plaque morphology in men with coronary disease who died suddenly.

Authors:  A P Burke; A Farb; G T Malcom; Y H Liang; J Smialek; R Virmani
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

4.  Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.

Authors:  E Ernst; K L Resch
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

5.  The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation.

Authors:  P Schuff-Werner; H Gohlke; U Bartmann; G Baggio; M C Corti; A Dinsenbacher; T Eisenhauer; P Grützmacher; C Keller; U Kettner
Journal:  Eur J Clin Invest       Date:  1994-11       Impact factor: 4.686

6.  Improvement of coronary vasodilatation capacity through single LDL apheresis.

Authors:  K P Mellwig; D Baller; U Gleichmann; D Moll; S Betker; R Weise; G Notohamiprodjo
Journal:  Atherosclerosis       Date:  1998-07       Impact factor: 5.162

7.  Plasma exchange in the management of homozygous familial hypercholesterolaemia.

Authors:  G R Thompson; R Lowenthal; N B Myant
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

8.  Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy.

Authors:  D M Lane; W J McConathy; L O Laughlin; P C Comp; B von Albertini; L A Bricker; P Kozlovskis; R S Lees; C Dorrier
Journal:  Atherosclerosis       Date:  1995-04-24       Impact factor: 5.162

9.  Inhibition by cholesterol oxides of NO release from human vascular endothelial cells.

Authors:  V Deckert; A Brunet; F Lantoine; G Lizard; E Millanvoye-van Brussel; S Monier; L Lagrost; M David-Dufilho; P Gambert; M A Devynck
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-07       Impact factor: 8.311

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  1 in total

1.  Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by in vivo high-resolution CMR--a comparative analysis.

Authors:  Jochen M Grimm; Konstantin Nikolaou; Andreas Schindler; Reinhard Hettich; Franz Heigl; Clemens C Cyran; Florian Schwarz; Reinhard Klingel; Anna Karpinska; Chun Yuan; Martin Dichgans; Maximilian F Reiser; Tobias Saam
Journal:  J Cardiovasc Magn Reson       Date:  2012-11-29       Impact factor: 5.364

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.